Donanemab was approved by the FDA in July 2024 to treat adults with early symptomatic Alzheimer's disease with confirmed ...

Alzheimer's disease progression linked to microglia fat metabolism, potential new treatment target identified in recent study ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats with cognitive decline, beyond the infamous amyloid and tau plaques long blamed for Alzheimer’s. These ...

For decades, Alzheimer’s disease has resisted nearly every significant pharmaceutical intervention. Despite billions invested ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

Researchers at the Federal University of São Carlos (UFSCar) in the state of São Paulo, Brazil, are developing a panel of ...

Newborns and individuals with Alzheimer's disease have been found to share an unusual biological feature: both show high ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Treating the neurodegenerative disease in its earlier stages is key to slowing cognitive decline. A new study offers hope for ...

For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of which can kill neurons and impact the brain’s abil ...